Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials
Supporting Files
-
-
-
-
Available in CDC Stacks on
File Language:
English
Details
-
Alternative Title:Eur J Cancer
-
Description:Introduction:
Disease-free survival (DFS) is increasingly being used as surrogate end-point for overall survival (OS) in cancer trials. So far, there has been no validation of the surrogacy of DFS for OS for neoadjuvant treatment of gastroesophageal adenocarcinoma.
Methods:
The study uses individual patient data (IPD) from eight randomised controlled trials (RCTs) (n = 1126 patients) comparing neoadjuvant therapy followed by surgery with surgery alone for gastroesophageal adenocarcinoma. Correlation between OS time and DFS time was calculated to evaluate individual-level surrogacy. For each trial, survival curves using the Kaplan-Meier method were plotted and hazard ratios (HRs) on the treatment effects were calculated for OS and DFS separately. Those HRs were pooled in a random-effects meta-analysis. Observed HRs were compared with predicted HRs for OS using results from an error-invariables linear regression model accounting for the uncertainty about the estimated effect. The strength of the association was quantified by the coefficient of determination to assess trial-level surrogacy. The surrogate threshold effect was calculated to determine the minimum treatment effect on DFS necessary to predict a non-zero treatment effect on OS.
Results:
A strong correlation between OS time and DFS time was observed, indicating a high individual-level surrogacy. For all RCTs, estimated HRs for OS and DFS were highly similar. In the meta-analysis, the overall HR for OS was virtually identical to that for DFS. The estimated coefficient of determination r2 for the association between HRs for OS and DFS was 0.912 (95% confidence interval: 0.75−1.0), indicating a very good fit of the regression model and thus a strong trial-level surrogacy between OS and DFS. The surrogate threshold effect based on the regression analysis was 0.79.
Discussion:
Based on strong correlations between DFS and OS, as well as a strong correlation of the treatment effects of the two end-points in the error-in-variable regression, DFS seems an appropriate surrogate marker for OS in randomised trials of neoadjuvant chemotherapy or chemoradiotherapy for gastroesophageal adenocarcinoma. -
Subjects:
- Article
- Gastroesophageal
- adenocarcinoma
- Neoadjuvant
- chemotherapy
- chemoradiotherapy
- Overall survival
- Disease-free survival
- Individual patient data
- meta-analysis
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers
- Chemoradiotherapy
- Digestive System Surgical Procedures
- Disease-Free Survival
- Esophageal Neoplasms
- Female
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
- Proportional Hazards Models
- Stomach Neoplasms
- Survival Rate
- Treatment Outcome
- Young Adult
-
Pubmed ID:31678767
-
Pubmed Central ID:PMC8767957
-
Document Type:
-
Funding:
-
Volume:123
-
Download URL:
-
File Type:
-
Collection(s):
-
Main Document Checksum:urn:sha256:cb6d411d99161a89ea4ace451e9f5a05168589e9c495e6be5ebb7a861b92d682
Supporting Files
File Language:
English
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings, journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
CDC Public Access